ArticleAntiviral research2022

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.

Daniele Focosi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.